Atherogenic lipoprotein particles in atherosclerosis

Circulation

Volumn 109, Issue 23 SUPPL., 2004, Pages

  Carmena, Rafael ^a   Duriez, Patrick ^b,c   Fruchart, Jean Charles ^b,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIV LILLE   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoprotein B; Lipoprotein(a); Low density lipoprotein; Triglyceride rich lipoproteins; Triglycerides

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG TARGETING; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ARTERIOSCLEROSIS; CENTRIFUGATION, DENSITY GRADIENT; CHOLESTEROL, LDL; CHROMATOGRAPHY, GEL; CORONARY ARTERIOSCLEROSIS; DISEASE SUSCEPTIBILITY; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARTICLE SIZE; RISK FACTORS; TRIGLYCERIDES;

EID: 2942750058     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Rainwater DL, Andres DW, Ford AL, et al. Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. J Lipid Res. 1992;33:1876-1881.
2. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
3. Scheffer PG, Bakker SJ, Heine RJ, et al. Measurement of LDL particle size in whole plasma and serum by high performance gel-filtration chromatography using a fluorescent lipid probe. Clin Chem. 1998;44:2148-2151.
4. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2002;22:1175-1180.
5. Chung BH, Segrest JP, Cone JT, et al. High resolution plasma lipoprotein cholesterol profiles by a rapid, high volume semi-automated method. J Lipid Res. 1981;22:1003-1014.
6. Kulkami KR, Garber DW, Marcovina SM, et al. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res. 1994;35:159-168.
7. Swinkels DW, Hak-Lemmers HL, Demacker PN. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low-density lipoprotein subfractions. J Lipid Res. 1987;28:1233-1239.
8. Skoglund-Andersson C, Tang R, Bond MG, et al. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol. 1999;19:2422-2430.
9. Lamarche B, St Pierre AC, Ruel IL, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 2001;17:859-865.
10. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
11. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:1046-1053.
12. Blake GJ, Otvos JD, Rifai N, et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930-1937.
13. Liu ML, Ylitalo K, Nuotio I, et al. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke. 2002;33:1255-1260.
14. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, pathophysiology and therapeutic aspects. Diabetes Metab. 1999;25:199-211.
15. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-462.
16. Soedamah-Muthu SS, Chang YF, Otvos J, et al. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes: a prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2003;46:674-682.
17. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003;107:1733-1737.
18. Steinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA. 1984;81:3883-3887.
19. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001:21:844-848.
20. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2243-2247.
21. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002;22:1162-1167.
22. Sherer Y, Tenenbaum A, Praprotnik S, et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, β-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology. 2001;95:20-24.
23. Erkkila AT, Narvanen O, Lehto S, et al. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:204-209.
24. Leinonen JS, Rantalaiho V, Laippala P, et al. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus. Free Radic Res. 1998;29:137-141.
25. Yusuf S, Dagenais G, Pogue J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.
26. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
27. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002;105:2107-2111.
28. Lee DM, Alaupovic P. Composition and concentration of apolipoproteins in very-low- and low-density lipoproteins of normal human plasma. Atherosclerosis. 1974;19:501-520.
29. Kwiterovich PO Jr, Coresh J, Smith HH, et al. Comparison of the plasma levels of apolipoproteins B and A-I, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 1992;69:1015-1021.
30. Sigurdsson G, Baldursdottir A, Sigvaldason H, et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.
31. Marcovina SM, Albers JJ, Kennedy H, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, IV: comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994;40:586-592.
32. Jungner I, Marcovina SM, Walldius G, et al. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem. 1998;44(8, pt 1):1641-1649.
33. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:273-278.
34. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.
35. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447-459.
36. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943-949.
37. Havel RJ. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation. 1990;81:694-696.
38. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B-17B.
39. Tkac I, Kimball BP, Lewis G, et al. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol. 1997;17:3633-3638.
40. Schaefer EJ, McNamara JR, Shah PK, et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care. 2002;25:989-994.
41. Kugiyama K, Doi H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999;99:2858-2860.
42. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
43. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
44. Alaupovic P, Mack WJ, Knight-Gibson C, et al. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-722.
45. Luc G, Fievet C, Arveiler D, et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur Infarctus du Myocarde. J Lipid Res. 1996;37:508-517.
46. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886-1892.
47. Durrington PN. Lipoprotein (a). Baillieres Clin Endocrinol Metab. 1995;9:773-795.
48. Seman LJ, DeLuca C, Jenner JL, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem. 1999;45:1039-1046.
49. Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 1998;44:2301-2306.
50. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis. 2002;163:377-384.